title: Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome.
abstract: Polycystic ovary syndrome (PCOS) is defined by menstrual irregularity, hyperandrogenism, chronic anovulation, and enlarged ovaries with multiple follicles. Polycystic ovary syndrome is highly prevalent in women, affecting up to 10% of all women of reproductive age and reducing the possibility of spontaneous conception. In addition to altering reproductive function, PCOS has systemic implications, especially in the cardiovascular system. Cardiovascular risk (CVR) in PCOS patient increases because of insulin resistance, elevated androgen levels, and association with obesity. Those alterations promote cardiovascular risk factors, such as endothelial dysfunction, elevated homocysteine levels, left ventricular hypertrophy, and reduced high-density lipoprotein (HDL) cholesterol (1).
authors.affiliation: Department of Obstetrics and Gynecology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil; Gynecology Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
authors.forename: Ivan
authors.initials: I
authors.lastname: Araujo Penna
authors.forename: Paulo Roberto Bastos
authors.initials: PR
authors.lastname: Canella
authors.forename: Carolina Sales
authors.initials: CS
authors.lastname: Vieira
authors.forename: Marcos Felipe
authors.initials: MF
authors.lastname: Silva de Sá
authors.forename: Rosana Maria
authors.initials: RM
authors.lastname: dos Reis
authors.forename: Rui Alberto
authors.initials: RA
authors.lastname: Ferriani
mesh_terms: D020909:Acarbose / Q000008:administration & dosage*; D000328:Adult; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D015243:Cholesterol, VLDL / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D017588:Hyperandrogenism / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D019007:P-Selectin / Q000097:blood; D010919:Placebos; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D015243:Cholesterol, VLDL; D007004:Hypoglycemic Agents; D019007:P-Selectin; D010919:Placebos; D020909:Acarbose